Quick Links

Michael Pollak

Michael Pollak

Director, Division of Cancer Prevention, Department of Oncology, McGill University
Alexander-Goldfarb Research Chair in Medical Oncology, McGill University
Professor, Departments of Medicine and Oncology, McGill University
Director, Cancer Prevention Centre, Segal Cancer Centre

Address
Jewish General Hospital
3755 Côte-Sainte-Catherine Road
Room E-763
Montreal, Quebec, Canada
H3T 1E2

Tel.: 514-340-8222 ext. 5530
Fax: 514-340-8600
michael [dot] pollak [at] mcgill [dot] ca ( Email )
Dr. Pollak's Website
McGill Cancer Prevention Program


Dr. Pollak’s Publications
To access Dr. Pollak's publications, please visit the McGill Pollak Research Lab.
Please note that the publications may also be viewed on Dr. Pollak’s profiles on Researcher ID and Microsoft Academic.


Expertise: Non-Cytotoxic Approaches To Cancer Therapy And Prevention

Summary of Research Activities
We have several ongoing projects to develop novel cancer therapies and cancer prevention strategies. Our research program includes basic work in cellular molecular biology, translational research, and clinical studies. Our basic studies concern the roles of peptide growth factors, particularly insulin-like growth factors, in the pathophysiology of neoplasia. We have demonstrated that many cancers are dependent on IGF stimulation, and shown that novel compounds that target IGF bioactivity deserve evaluation as cancer therapies. Our studies provide evidence that IGF signaling plays roles in clinically important challenges including development of resistance to Herceptin in breast cancer, and progression of prostate cancer to androgen-independence. We also have identified IGF physiology as an area that may lead to novel prevention strategies, both for the general population and for individuals at increased genetic risk for cancer. In collaboration with colleagues at the Harvard School of Public Health, we have shown that high circulating levels of IGF-I represent an important risk factor for several common cancers. We now are studying the mechanisms underlying the relationship between IGF-I levels and risk of neoplasia.

Recent Publications
Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology.Clini Cancer Res 18: 40-50, 2012. Times cited (as of 2012): 3

*Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli LA, Birman E, Viollet B, Ferbeyre G, Pollak MN. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) 5: 536-43, 2012.

Agurs-Collins T, Rohrmann S, Sutcliffe C, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Platz EA. Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. Cancer Causes Control 23: 445-54, 2012.

Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN, Le Marchand L. Genetic variants, prediagnostic levels of insulin-like growth factors, insulin and glucose, and the risk of colorectal cancer: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 21: 810-20, 2012.

Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-69, 2012.

Faupel-Badger JM, Wang Y, Staff AC, Karumanchi SA, Stanczyk FZ, Pollak M, Hoover RN, Troisi R. Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes Control23: 779-84, 2012.

Zhang X, Giovannucci EL, Wu K, Smith-Warner SA, Fuchs CS, Pollak M, Willett WC, Ma J. Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. Br J Cancer 106: 1335-41, 2012.

Rice MS, Tamimi RM, Connolly JL, Collins LC, Shen D, Pollak MN, Rosner B, Hankinson SE, Tworoger SS. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses’ Health Study II. Breast Cancer Res 14: R44, 2012.

Pollak M, Gonzalez-Angulo AM. Metformin and hepatic carcinogenesis.Cancer Prev Res (Phila) 5: 500-2, 2012.

Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res 18: 2723-5, 2012.

Kaplan RC, Buzkova P, Cappola AR, Strickler HD, McGinn AP, Mercer LD, Arnold AM, Pollak MN, Newman AB. Decline in circulating insulin-like growth factors and mortality in older adults: Cardiovascular Health Study All-Stars Study. J Clin Endocrinol Metab 97: 1970-6, 2012.

Rajpathak SN, HE M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, Gunter MJ, Pollak M, Kim M, Pessin JE, Beasley J, Wylie-Rosett J, Hu FB, Strickler HD. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012 May 3. Epub ahead of print.

Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker AV, Pollak MN. A phase 2 pharmacodynamic study of pre-operative figitumumab in patients with localized prostate cancer. Clin Cancer Res 18: 3407-13, 2012.

Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The interactions between insulin and androgens in progression to castrate-resistant prostate cancer.Adv Urol 2012: 248607, 2012.

Fung TT, Hu FB, Schulze M, Pollak M, Wu T, Fuchs CS, Giovannucci E. A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. Cancer Causes Control 23: 959-65, 2012.

Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012 May 22. Epub ahead of print.

Jenkins CR, Schevchuk OO, Giambra V, Lam SH, Carboni JM, Gottardis MM, Holzenberger M, Pollak M, Humphries RK, Weng AP. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Exp Hematol 40: 715-723, 2012.

Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, Sonenberg N. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci USA 109: 8977-82, 2012.

Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JR, Nagendran J, Flores CT, Betof AS, Nelson ER, Pollak M, Dash RC, Young ME, Freedland SJ. Exercise modulation of the host – tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol 113: 263-72, 2012.

Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S.The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344:e3645, 2012.

*Hvid H, Fendt SM, Blouin MJ, Birman E, Voisin G, Svendsen AM, Frank R, Vander Heiden MG, Stephanopoulos G, Hansen BF, Pollak MN. Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocr Relat Cancer 19: 557-74, 2012.

Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55: 1619-32, 2012.

Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55: 1607-18, 2012.

Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2, and IGFBP3 and risk of advanced colorectal adenoma.Int J Cancer 131: E105-13, 2012.

Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, Pollak M, Morin GB, Sorensen PH. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 31: 1334-40, 2012.

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor in breast cancer subtypes. Breast Cancer Res Treat 132: 131-42, 2012.

Runchey SS, Pollak MN, Valsta LM, Coronado GD, Schwarz Y, Breymeyer KL, Wang C, Wang CY, Lampe JW, Neuhouser ML. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study.Eur J Clin Nutr. 2012 Aug 15.Epub ahead of print.

Pollak M. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2: 778-90, 2012.